Consensus document on the use of sacubitril/valsartan in patients with heart failure: Consejo Interamericano de Falla Cardiaca e Hipertensión Pulmonar (CIFACAH) of the Inter-American Society of Cardiology (IASC)

Speranza M.; Saldarriaga C.; Ramos C.E.; Quesada D.; Rossel V.; Ventura-Umanzor J.R.; Pow-Chon F.; Alarco W.; Figueroa Y.; Magaña A.; Gómez-Mesa J.E.; Rodríguez-García D. · Archivos de Cardiologia de Mexico (2023) · DOI: 10.24875/acm.23000036

Resumen

Heart failure (HF) is a significant event for public health. It has a prevalence between 1-2%, mortality rate between 7-17%, and hospitalization between 32-44%. This implies a risk to health and quality of life, but also great financial efforts for health systems. Sacubitril/valsartan is a medication recognized for its efficacy, and this consensus seeks to synthesize the available information regarding its use for the benefit of patients. This document consists of a description of the epidemiology of HF, pharmacology of the drug, clinical trials, use of the drug in cases with reduced ejection fraction, mildly reduced ejection fraction and preserved ejection fraction, available literature on HF guidelines, recommendations and conclusions.